RESUMEN
It has been known for over half a century that liver cirrhosis is associated with abnormal cardiovascular function. Although the mechanisms underlying the association of portal hypertension and hyperdynamic circulation have been intensively investigated during the past decades, the results are still inconclusive. This review focuses on the role that the endocannabinoids and their receptors could play in the pathogenesis of the cirrhotic cardiomyopathy, as well as on the treatment options that they offer.
Asunto(s)
Antagonistas de Receptores de Cannabinoides/uso terapéutico , Cardiomiopatías , Endocannabinoides/fisiología , Hemodinámica , Cirrosis Hepática/complicaciones , Cardiomiopatías/etiología , Cardiomiopatías/metabolismo , Cardiomiopatías/prevención & control , Humanos , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/metabolismo , PronósticoRESUMEN
In the treatment of depression fluoxetine [a selective serotonine reuptake inhibitor (SSRIs)] is a widely used drug in humans. The selectivity, efficacy, side effects and simplicity of dosage contributed to fluoxetine's clinical acceptance. Several psychiatric disorders (many of them responsive to SSRIs) are present during pregnancy; up to 10% of pregnant women fulfill diagnostic criteria for major or minor depression with an even higher percentage developing postpartum depression. Therefore, significant numbers of women may be taking SSRIs while pregnant. Since fluoxetine's safe use during pregnancy is not yet established and experimental studies inconclusive, we performed the present research in order to investigate the neurobehavioral effects produced in rats by prenatal exposure to fluoxetine (5 and 10 mg/kg/sc from day 13 to 20 of gestation) on cognitive functions, emotional reactivity and sexual performance.